Lots of people are pointing to dosing and the AEs, but that's obviously irrelevant if the exon skipping is being promoted. IF these patients in the drisa trial had exon skipping and dystrophin production, then that's bad news for SRPT.
I'll be interested to see dystrophin data from this trial. The dystrophin data released by SRPT was spotty and unimpressive, so a more comprehensive report from this drisa trial will be nice to see.
News 
Market Data 
Discover 
